A detailed history of Citigroup Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Citigroup Inc holds 118,182 shares of MYGN stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118,182
Previous 82,978 42.43%
Holding current value
$1.62 Million
Previous $2.03 Million 59.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.97 - $28.6 $843,839 - $1.01 Million
35,204 Added 42.43%
118,182 $3.23 Million
Q2 2024

Aug 12, 2024

SELL
$17.98 - $25.47 $3.31 Million - $4.69 Million
-184,128 Reduced 68.93%
82,978 $2.03 Million
Q1 2024

May 10, 2024

BUY
$17.59 - $23.59 $2.6 Million - $3.48 Million
147,679 Added 123.66%
267,106 $5.69 Million
Q4 2023

Feb 09, 2024

SELL
$13.91 - $21.32 $32,730 - $50,165
-2,353 Reduced 1.93%
119,427 $2.29 Million
Q3 2023

Nov 09, 2023

BUY
$15.99 - $23.22 $92,726 - $134,652
5,799 Added 5.0%
121,780 $1.95 Million
Q2 2023

Aug 10, 2023

SELL
$17.56 - $23.76 $1.04 Million - $1.4 Million
-59,092 Reduced 33.75%
115,981 $2.69 Million
Q1 2023

May 11, 2023

BUY
$15.26 - $23.75 $501,901 - $781,137
32,890 Added 23.13%
175,073 $4.07 Million
Q4 2022

Feb 09, 2023

SELL
$14.51 - $20.99 $802,693 - $1.16 Million
-55,320 Reduced 28.01%
142,183 $2.06 Million
Q3 2022

Nov 10, 2022

BUY
$18.21 - $27.88 $879,215 - $1.35 Million
48,282 Added 32.36%
197,503 $3.77 Million
Q2 2022

Aug 10, 2022

BUY
$16.45 - $25.88 $699,733 - $1.1 Million
42,537 Added 39.87%
149,221 $2.71 Million
Q1 2022

May 12, 2022

SELL
$22.67 - $28.01 $2.45 Million - $3.02 Million
-107,972 Reduced 50.3%
106,684 $2.69 Million
Q4 2021

Feb 10, 2022

BUY
$24.13 - $32.63 $1.98 Million - $2.68 Million
81,995 Added 61.81%
214,656 $5.93 Million
Q3 2021

Nov 10, 2021

BUY
$29.97 - $36.66 $3.98 Million - $4.86 Million
132,661 New
132,661 $4.28 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.11B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.